Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical significance of mitochondrial DNA content in acute promyelocytic leukaemia.
Pereira-Martins DA, Coelho-Silva JL, Weinhäuser I, Franca-Neto PL, Silveira DR, Ortiz C, Moreira-Aguiar A, Lima MM, Koury LC, de Melo RA, Glória AB, Fagundes EM, Lino BK, Pagnano K, Bittencourt R, Nunes E, Traina F, Figueiredo-Pontes L, Keating A, Tallman MS, Ribeiro RC, Dilon R, Ganser A, Sanz MA, Berliner N, Valk P, Löwenberg B, Ottone T, Noguera NI, Voso MT, Paoloni F, Fazi P, Ammatuna E, Huls G, Schuringa JJ, Rego EM, Lucena-Araujo AR. Pereira-Martins DA, et al. Among authors: figueiredo pontes l. Br J Haematol. 2023 Jan;200(2):170-174. doi: 10.1111/bjh.18510. Epub 2022 Oct 20. Br J Haematol. 2023. PMID: 36263593
Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model.
Alves-Silva AB, Fenerich BA, Fonseca NP, Fernandes JC, Coelho-Silva JL, Pereira-Martins DA, Bianco TM, Scheucher PS, Rego EM, Chahud F, Machado-Neto JA, Figueiredo-Pontes LL, Traina F. Alves-Silva AB, et al. Invest New Drugs. 2022 Jun;40(3):576-585. doi: 10.1007/s10637-022-01212-y. Epub 2022 Jan 11. Invest New Drugs. 2022. PMID: 35015172
Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2V617F driven cells.
Fernandes JC, Fenerich BA, Alves-Silva AB, Fonseca NP, Coelho-Silva JL, Scheucher PS, Rego EM, Figueiredo-Pontes LL, Machado-Neto JA, Traina F. Fernandes JC, et al. Among authors: figueiredo pontes ll. Toxicol In Vitro. 2022 Sep;83:105384. doi: 10.1016/j.tiv.2022.105384. Epub 2022 May 11. Toxicol In Vitro. 2022. PMID: 35568132 Free article.
Results of FLT3 mutation screening and correlations with immunophenotyping in 169 Brazilian patients with acute myeloid leukemia.
Lucena-Araujo AR, Souza DL, Morato de Oliveira F, Benicio MT, Figueiredo-Pontes LL, Santana-Lemos BA, dos Santos GA, Jacomo RH, Dinarte-Santos AR, Yamamoto M, Silva WA Jr, de Lourdes Chauffaille M, Rego EM. Lucena-Araujo AR, et al. Ann Hematol. 2010 Feb;89(2):225-8. doi: 10.1007/s00277-009-0817-4. Ann Hematol. 2010. PMID: 19921191 No abstract available.
Dysregulation of interferon regulatory genes reinforces the concept of chronic immune response in myelodysplastic syndrome pathogenesis.
de Sousa JC, da Nóbrega Ito M, Costa MB, Farias IR, de Paula Borges D, de Oliveira RT, Fukutani KF, Thomé CH, da Silva Martinelli CM, Myajima F, Vidal DO, Magalhães SMM, Figueiredo-Pontes LL, Pinheiro RF. de Sousa JC, et al. Hematol Oncol. 2019 Oct;37(4):523-526. doi: 10.1002/hon.2608. Epub 2019 Jul 15. Hematol Oncol. 2019. PMID: 30920666 No abstract available.
Clinical networking results in continuous improvement of the outcome of patients with acute promyelocytic leukemia.
Koury LCA, Kim HT, Undurraga MS, Navarro-Cabrera JR, Salinas V, Muxi P, Melo RAM, Gloria ABF, Pagnano KBB, Nunes EC, Bittencourt RI, Rojas N, Quintana Truyenque SM, Ayala-Lugo AI Dr, Oliver AC, de Figueiredo-Pontes LL, Traina F, Moreira F, Fagundes EM, Duarte BKL, Mora-Alferez AP, Ortiz P, Untama JL, Tallman MS, Ribeiro RC, Ganser A, Dillon RJ, Valk PJM, Sanz MA, Löwenberg B, Berliner N, Rego EM. Koury LCA, et al. Among authors: de figueiredo pontes ll. Blood. 2024 May 28:blood.2024023890. doi: 10.1182/blood.2024023890. Online ahead of print. Blood. 2024. PMID: 38805638
Kinetics of BCR::ABL1 transcript levels and molecular relapse after tyrosine kinase inhibitors discontinuation in chronic myeloid leukemia patients: preliminary results from the DES-CML study.
Murbach B, Duarte G, Palma LC, Miranda E, Duffles G, Furlin GP, Toni I, De Souza C, Binelli L, Bassan VL, de Castro FA, de Figueiredo-Pontes LL, Pagnano KBB. Murbach B, et al. Among authors: de figueiredo pontes ll. Front Oncol. 2024 May 8;14:1393191. doi: 10.3389/fonc.2024.1393191. eCollection 2024. Front Oncol. 2024. PMID: 38779092 Free PMC article.
42 results